Browsing Tag
BioWa
1 post
AstraZeneca’s Fasenra misses primary endpoint in COPD trial but keeps investor confidence alive
AstraZeneca’s Fasenra failed to hit its COPD trial endpoint, but stock rose 0.44% as investors bet on pipeline strength and respiratory growth.